These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33419370)

  • 1. Pharmacogenetics Update on Biologic Therapy in Psoriasis.
    Muñoz-Aceituno E; Martos-Cabrera L; Ovejero-Benito MC; Reolid A; Abad-Santos F; Daudén E
    Medicina (Kaunas); 2020 Dec; 56(12):. PubMed ID: 33419370
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis.
    van Vugt LJ; van den Reek JMPA; Coenen MJH; de Jong EMGJ
    Br J Dermatol; 2018 Jan; 178(1):86-94. PubMed ID: 28646581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.
    Ovejero-Benito MC; Muñoz-Aceituno E; Sabador D; Almoguera B; Prieto-Pérez R; Hakonarson H; Coto-Segura P; Carretero G; Reolid A; Llamas-Velasco M; Abad-Santos F; Daudén E
    Exp Dermatol; 2020 Dec; 29(12):1225-1232. PubMed ID: 33058233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.
    Loft ND; Skov L; Iversen L; Gniadecki R; Dam TN; Brandslund I; Hoffmann HJ; Andersen MR; Dessau RB; Bergmann AC; Andersen NM; Andersen PS; Bank S; Vogel U; Andersen V
    Pharmacogenomics J; 2018 May; 18(3):494-500. PubMed ID: 28696418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.
    Masouri S; Stefanaki I; Ntritsos G; Kypreou KP; Drakaki E; Evangelou E; Nicolaidou E; Stratigos AJ; Antoniou C
    Mol Diagn Ther; 2016 Jun; 20(3):221-5. PubMed ID: 27043841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
    Connell WT; Hong J; Liao W
    Front Immunol; 2021; 12():815121. PubMed ID: 35154085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López-Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics J; 2018 Jan; 18(1):70-75. PubMed ID: 27670765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
    Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
    Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
    JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.
    Berna-Rico E; Perez-Bootello J; Abbad-Jaime de Aragon C; Gonzalez-Cantero A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.
    Membrive Jiménez C; Pérez Ramírez C; Sánchez Martín A; Vieira Maroun S; Arias Santiago SA; Ramírez Tortosa MDC; Jiménez Morales A
    J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33921427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
    Yeh NL; Hsu CY; Tsai TF; Chiu HY
    Clin Drug Investig; 2019 Dec; 39(12):1195-1203. PubMed ID: 31549347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
    Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
    Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.